spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  cancer cachexia 

 HSMN NewsFeed - 2 Feb 2021
Actimed Therapeutics Appoints Frank Misselwitz MD, PhD as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Aug 2016
Acacia Pharma Announces Positive Results From a Pivotal Phase 3 Trial of BAREMSIS(TM) for the Treatment of Post-Operative Nausea & Vomiting
Biopharmaceuticals
 HSMN NewsFeed - 16 Feb 2016
Helsinn Group Signs Exclusive Agreement With Mundipharma for the Distribution and Licence of Anamorelin in Northern Europe Countries
Biopharmaceuticals Oncology Licensing Distribution
 HSMN NewsFeed - 10 Nov 2015
Hi-Tech Pharmaceuticals Files Lawsuit Against IronMag Labs and Robert Dimaggio Over Racketeer Influenced and Corrupt Organizations (RICO) and Patent Infringement
Biopharmaceuticals Litigation
 HSMN NewsFeed - 3 Sep 2015
Helsinn Group Signs Exclusive Agreement With Mundipharma for the Distribution and Licence of anamorelin in Switzerland and Liechtenstein
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 4 Apr 2014
GTx Announces Departure of CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 May 2013
Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 May 2012
FDA Grants Fast Track Designation to Ohr Pharmaceutical's Squalamine Eye Drops for the Treatment of Wet-AMD
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 27 Apr 2009
First Ever Prospective Fracture Study in Prostate Cancer Patients on ADT Reveals These Men Are at High Risk for Skeletal Fractures
Biopharmaceuticals Oncology Urology
 HSMN NewsFeed - 28 Jan 2009
Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 7 Jul 2008
Inovio Biomedical and VGX Pharmaceuticals Sign Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 6 May 2008
GTx Appoints Kenneth S. Robinson, MD to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Mar 2008
GTx Announces Additional Top Line Phase III Data Demonstrating Toremifene Citrate 80 mg Reduced Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Feb 2008
GTx's Toremifene Citrate 80 mg Meets Primary and Key Endpoints in Phase III Trial in Advanced Prostate Cancer Patients on Androgen Deprivation Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Jul 2007
GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review
Biopharmaceuticals
 HSMN NewsFeed - 17 Apr 2007
GTx Announces Ostarine(TM) Improved Insulin Resistance among Elderly Patients in a Recently Completed Phase II Clinical Trial
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 10 Apr 2007
GTx, Inc. Appoints Jeff Hesselberg as Vice President of Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Apr 2007
GTx, Inc. Appoints Ronald A. Morton, Jr. MD, FACS as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Mar 2007
Sapphire Therapeutics, Inc. Promotes William Polvino to CEO, Herb Conrad Elected Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Feb 2007
GTx's ACAPODENE Interim Bone Mineral Density and Lipid Data Highlighted at Press Briefing at Prostate Cancer Symposium of the American Society of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Feb 2007
GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Jan 2007
Vicus Therapeutics Announces the FDA has Allowed the Phase 2 Trial of VT-122 for the Treatment of Cachexia in Patients With Advanced Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Dec 2006
GTx Announces That Ostarine Achieved Primary Endpoint of Lean Body Mass and a Secondary Endpoint of Improved Functional Performance in a Phase II Clinical Trial and Reacquisition of Full Rights to GTx SARM Program
Biopharmaceuticals
 HSMN NewsFeed - 28 Nov 2006
Elixir Pharmaceuticals Raises $46 Million
Biopharmaceuticals Venture Capital
Return to NewsFeed  

 Additional items found! 11

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 11 additional stories matching:
cancer cachexia
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.